首頁
Five Prime Therapeutics, Inc.

3月 2026Five Prime Therapeutics,...的市場佔有率分析

To support Amgen’s mission of serving patients, the R&D organization aims to discover, develop, and deliver transformative medicines that address the leading causes of death and disability, working to meet the needs of as many patients as possible.

健康 > 生物技術和製藥

域名fiveprime.com

成立年份2001

僱員51 - 200

年度營收$25M - $50M

Five Prime Therapeutics, Inc.

Five Prime Therapeutics, Inc.（包含公司地區）

fiveprime.com

查看更多網站流量與參與度資訊

Five Prime Therapeutics, Inc.截至 3月 2026 的總收入為 25M - 50M

Five Prime Therapeutics, Inc. 熱門網域產生的總收入

Five Prime Therapeutics, Inc. 熱門網域 3 年內的總收入

Five Prime Therapeutics, Inc. 熱門網域的總收入

fiveprime.com25M - 50M

透過銷售情報查看更多內容

Five Prime Therapeutics, Inc.的熱門網域總造訪量

了解Five Prime Therapeutics, Inc.市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

無可顯示數據

Five Prime Therapeutics, Inc.的熱門網域平均造訪時長

分析Five Prime Therapeutics, Inc.參與度指標。

過去 3 個月平均造訪時長

無可顯示數據

Five Prime Therapeutics, Inc.的熱門網域平均頁面瀏覽量

了解Five Prime Therapeutics, Inc.如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

無可顯示數據

Five Prime Therapeutics, Inc.按網域劃分的熱門競爭對手

3月 2026的熱門類似網站，依相似度排名

oncomed.com公司名OncoMed Pharmaceuticals僱員51 - 200總部美國, 加利福尼亞, Redwood City年度營收$25M - $50M訪問總量1.5K健康 > 生物技術和製藥

使用的熱門技術Five Prime Therapeutics, Inc.

这些是Five Prime Therapeutics, Inc.顶级域名使用的行业网站技术

音訊視訊媒體 (1)

YouTube

企業解決方案 (1)

DocuSign

內容管理系統 (1)

Web Dot Com

轉換與分析 (1)

Google Analytics

更多技術

4

檢視所有

新聞與訊號來自Five Prime Therapeutics, Inc.

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Zai Lab, Ltd. partners with Fiveprime.Previously, Zai Lab collaborated with Five Prime Therapeutics, a company later acquired by Amgen, to evaluate bemarituzumab plus chemotherapy (modified FOLFOX6) as a frontline targeted treatment for FGFR2b+ gastric and GEJ cancers in the Phase 2 FIGHT study.

新聞Collins leaves Fiveprime as Chief Medical Officer.Dr. Collins joins Enliven as a board-certified oncologist after serving as Chief Medical Officer at Five Prime Therapeutics through its acquisition by Amgen.

新聞Roche SA partnered with Fiveprime on May 1st '18.For instance, in May 2018, F. Hoffmann-La Roche AG, a Swiss multinational healthcare company, collaborated with Five Prime Therapeutics, Inc., a clinical stage biotechnology company, to provide IHC companion diagnostic assays for use with Five Prime’s, bemarituzumab, which is an investigational anti-FGFR2b antibody.